Recent advances in clinical genomics have revolutionized pediatric neurology by uncovering pathogenic drivers behind complex congenital anomalies and intellectual disabilities. Recently, researchers identified DDX39B neurodevelopmental syndrome as a distinct clinical entity linked to pathogenic alterations in basic RNA processing pathways. The DDX39B gene encodes a highly conserved ATP-dependent DEAD-box RNA helicase. This helicase operates directly within the transcription-export super protein complex, an indispensable multi-protein machinery governing messenger RNA biogenesis and nucleocytoplasmic export. When de novo or inherited pathogenic variants disrupt this fundamental molecular mechanism, affected children present with multisystemic neurological and physical abnormalities. Consequently, understanding this newly recognized syndrome allows clinicians to increase diagnostic yields, interpret complex genomic datasets, and offer tailored supportive care for affected pediatric patients.

Unraveling the Pathophysiology of DDX39B Neurodevelopmental Syndrome

The Transcription-Export (TREX) super protein complex plays an indispensable role in eukaryotic cellular physiology. Specifically, it coordinates the transcription, splicing, and nucleocytoplasmic transport of mature messenger RNA transcripts. DDX39B functions as an essential catalytic component within this multiprotein assembly. It facilitates spliceosome recruitment, promotes ATP hydrolysis, and mediates the loading of export factors onto nascent pre-mRNAs. Recent investigations demonstrate that heterozygous de novo missense alterations and splice-site mutations in DDX39B severely disrupt these vital cellular operations.

Furthermore, three-dimensional molecular modeling indicates that patient-derived variants alter critical functional domains of the RNA helicase. In vitro cellular studies confirm that specific mutations, such as p.(Gly92Asp) and c.433-1G>T, impair crucial protein-protein interactions within the TREX complex. Consequently, these structural disruptions prevent proper complex assembly. Meanwhile, other missense variants compromise catalytic ATPase activity without preventing physical association. Transcriptomic analyses in affected individuals reveal a massive accumulation of aberrant splicing events and impaired mRNA export signatures. In vivo functional assays in Drosophila and zebrafish models show that patient mutations act via loss-of-function mechanisms. Therefore, DDX39B dysfunction directly destabilizes the delicate balance of post-transcriptional gene regulation during critical stages of central nervous system maturation.

Core Clinical Features and Phenotypic Spectrum

Patients with this novel disorder display a recognizable yet variable constellation of multisystem features. Most affected individuals present early in infancy with profound congenital hypotonia and delayed motor milestone acquisition. Additionally, intellectual disability and global developmental delay represent universal findings across documented clinical cohorts. Speech development is frequently absent or severely limited, reflecting marked cortical involvement.

Furthermore, progressive microcephaly occurs in a significant proportion of diagnosed individuals, underscoring impaired prenatal and postnatal brain growth. Neurological manifestations frequently include early-onset epilepsy, varying from focal seizures to generalized tonic-clonic convulsions. Besides neurological findings, affected children exhibit proportionate or disproportionate short stature alongside characteristic skeletal anomalies. These skeletal anomalies encompass scoliosis, joint contractures, pectus deformities, and digital malformations. Dysmorphic facial features provide additional diagnostic clues, including prominent ears, high-arched palate, and hypertelorism. Moreover, gastrointestinal dysfunction frequently complicates clinical care, manifesting as severe neonatal feeding difficulties, gastroesophageal reflux, and poor weight gain. Because these features overlap with other genetic neurodevelopmental syndromes, comprehensive phenotypic characterization remains vital for guiding downstream genomic investigations.

Molecular Mechanisms and Disrupted mRNA Export

The pathobiology of DDX39B-related disease highlights the critical vulnerability of human neurodevelopment to defects in RNA metabolism. During embryogenesis, neural progenitor cells require precise temporal and spatial regulation of gene expression. DDX39B ensures that newly transcribed mRNAs undergo accurate intron excision before entering nuclear pore export channels. However, pathogenic variants disrupt this tightly orchestrated coordination.

Consequently, defective helicase activity triggers premature RNA degradation, abnormal intron retention, and nuclear entrapment of essential developmental transcripts. Blood transcriptomics in affected patients demonstrated significant increases in mis-spliced transcripts across thousands of neuronal and housekeeping genes. In addition, experimental modeling in animal models corroborated these devastating developmental effects. For example, antisense morpholino knockdown of DDX39B in zebrafish embryos generated microcephaly, shortened body axis, and aberrant motor behaviors. Remarkably, introducing wild-type human mRNA rescued this phenotype, whereas patient-derived mutant mRNAs failed to restore normal anatomy. Similarly, transgenic Drosophila studies confirmed that clinical variants represent loss-of-function alleles rather than dominant-negative entities. Therefore, defective mRNA transport and aberrant splicing represent the primary mechanistic drivers of widespread neurodevelopmental impairment.

Diagnostic Pathways and Exome Sequencing in Clinical Practice

Establishing a definitive diagnosis for children with rare neurodevelopmental disorders often requires advanced genomic technologies. In routine clinical practice, standard karyotyping and chromosomal microarray analysis usually fail to identify subtle point mutations in DDX39B. Therefore, clinicians must utilize next-generation sequencing approaches, particularly trio whole-exome sequencing (WES) or whole-genome sequencing (WGS).

Furthermore, because several identified pathogenic variants arise de novo, parental sequencing provides vital clarification regarding variant pathogenicity. When encountering novel variants of uncertain significance, clinicians can leverage specialized transcriptomic profiling or RNA sequencing from peripheral blood. This approach confirms aberrant splicing events in vivo and validates functional pathogenicity. Additionally, neuroimaging via magnetic resonance imaging (MRI) should complement genetic evaluation. Brain MRI scans frequently reveal cerebral cortical atrophy, corpus callosum hypoplasia, delayed myelination, and cerebellar volume loss. Clinicians should differentiate this condition from other established TREX complex disorders, such as THOC2- and THOC6-related syndromes. By combining precise deep phenotyping with comprehensive genomic testing, clinicians can avoid protracted diagnostic odysseys and provide families with clear answers and recurrence risk counseling.

Multidisciplinary Management and Future Therapeutic Horizons

Currently, curative therapies for DDX39B-related neurodevelopmental disorder do not exist, making proactive multidisciplinary care the cornerstone of clinical management. Pediatric neurologists play a central role in controlling epilepsy through customized antiepileptic drug regimens tailored to specific seizure semiologies. Furthermore, early intervention with intensive physiotherapy and occupational therapy addresses congenital hypotonia, prevents joint contractures, and supports motor skill acquisition.

In addition, pediatric gastroenterologists and nutritionists must assess feeding safety promptly to mitigate aspiration risks and ensure adequate caloric intake via gastrostomy feeding when indicated. Orthopedic surgeons monitor and manage emerging scoliosis, while speech and language therapists implement augmentative and alternative communication strategies. Medical geneticists provide vital reproductive counseling to families, assessing recurrence risks based on de novo versus inherited transmission patterns. Looking forward, emerging molecular therapies offer substantial promise. Because the pathology stems from loss-of-function RNA helicase defects and splicing errors, future translational efforts may explore antisense oligonucleotides (ASOs), gene replacement vectors, or small-molecule RNA modulators. Continued global patient registries will undoubtedly refine natural history data and accelerate clinical trial readiness for targeted therapeutics.

Frequently Asked Questions

What is the primary genetic cause of DDX39B neurodevelopmental syndrome?

DDX39B neurodevelopmental syndrome results from de novo missense variants or inherited splice-site mutations in the DDX39B gene. This gene encodes an essential ATP-dependent RNA helicase within the TREX super protein complex. Consequently, these deleterious genetic alterations impair pre-mRNA splicing and nuclear export, leading to profound downstream disruptions in neural development and cellular homeostasis.

What clinical features should raise suspicion for DDX39B neurodevelopmental syndrome?

Clinicians should suspect this condition in infants and children presenting with unexplained congenital hypotonia, global developmental delay, and progressive microcephaly. Furthermore, additional clinical hallmarks include refractory epilepsy, skeletal abnormalities, short stature, feeding difficulties, and distinct craniofacial dysmorphisms. Genetic testing remains essential to differentiate this rare presentation from other syndromic neurodevelopmental disorders.

How can clinicians diagnose and manage DDX39B neurodevelopmental syndrome?

Clinicians establish the diagnosis through comprehensive trio whole-exome or whole-genome sequencing combined with functional transcriptomic validation when necessary. Currently, management remains supportive and symptomatic. Care requires a multidisciplinary team involving pediatric neurologists, medical geneticists, orthopedic surgeons, physiotherapists, and speech pathologists to optimize neurodevelopmental outcomes and manage recurring seizures effectively.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should rely on their clinical judgment and confirmed laboratory or genetic diagnostic pathways. Refer to the latest local and national guidelines for clinical practice.

References

1. Booth KTA et al. De novo and inherited variants in DDX39B cause a novel neurodevelopmental syndrome. Brain. 2025 Aug 01. doi: 10.1093/brain/awaf035. PMID: 39918047.
2. Heath CG, Viphakone N, Wilson SA. Transcription-Export complex in neurodevelopmental disorders. Front Mol Biosci. 2024;11:1350291. doi: 10.3389/fmolb.2024.1350291.
3. Chung BHY, Vetrini F, Mak CCY. DEAD-box helicases in human neurogenesis and genetic disorders. Hum Mol Genet. 2025;34(R1):R12-R25.